A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6)

Study ID: 5508
NCT Number: NCT06193889
Principal Investigator: Richard Barohn, MD
Department: Health Affairs
Eligibility: Both men and women 18 years old to 75 years old. Accepts healthy volunteers.